Cargando…
The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma
Long non-coding RNAs (lncRNAs) are an important class of epigenetic regulators involved in both physiological processes and cancer development. Preliminary evidence suggested that lncRNAs could act as accurate prognostic and diagnostic biomarkers. Parathyroid cancer is a rare endocrine neoplasia, wh...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108332/ https://www.ncbi.nlm.nih.gov/pubmed/35586620 http://dx.doi.org/10.3389/fendo.2022.869006 |
_version_ | 1784708678835765248 |
---|---|
author | Morotti, Annamaria Cetani, Filomena Passoni, Giulia Borsari, Simona Pardi, Elena Guarnieri, Vito Verdelli, Chiara Tavanti, Giulia Stefania Valenti, Luca Bianco, Cristiana Ferrero, Stefano Corbetta, Sabrina Vaira, Valentina |
author_facet | Morotti, Annamaria Cetani, Filomena Passoni, Giulia Borsari, Simona Pardi, Elena Guarnieri, Vito Verdelli, Chiara Tavanti, Giulia Stefania Valenti, Luca Bianco, Cristiana Ferrero, Stefano Corbetta, Sabrina Vaira, Valentina |
author_sort | Morotti, Annamaria |
collection | PubMed |
description | Long non-coding RNAs (lncRNAs) are an important class of epigenetic regulators involved in both physiological processes and cancer development. Preliminary evidence suggested that lncRNAs could act as accurate prognostic and diagnostic biomarkers. Parathyroid cancer is a rare endocrine neoplasia, whose management represents a clinical challenge due to the lack of accurate molecular biomarkers. Our previous findings showed that human parathyroid tumors are characterized by a different lncRNAs signature, suggesting heterogeneity through the different histotypes. Particularly, we found that the lncRNA BC200/BCYRN1 could represent a candidate biomarker for parathyroid carcinomas (PCas). Here we aimed to extend our preliminary data evaluating whether BC200 could be an accurate non-invasive biomarker of PCas to support the clinical management of patients affected by parathyroid tumors at diagnosis, prognosis and follow-up. To provide a non-invasive point-of-care for parathyroid carcinoma diagnosis and follow-up, we analyzed BC200 expression in patients’ serum through digital PCR. Our results show that BC200 counts are higher in serum from patients harboring PCa (n=4) compared to patients with parathyroid adenoma (PAd; n=27). Further, in PAd patients circulating BC200 levels are positively correlated with serum total calcium. Then, we found that BC200 is overexpressed in metastatic PCas (n=4) compared to non-metastatic ones (n=9). Finally, the lncRNA expression in PCa patients’ serum drops are reduced after parathyroidectomy, suggesting its possible use in the post-operative setting for patients follow-up. Overall, these findings extend the knowledge on BC200 in parathyroid tumors, supporting its role as a useful biomarker for management of PCa. |
format | Online Article Text |
id | pubmed-9108332 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91083322022-05-17 The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma Morotti, Annamaria Cetani, Filomena Passoni, Giulia Borsari, Simona Pardi, Elena Guarnieri, Vito Verdelli, Chiara Tavanti, Giulia Stefania Valenti, Luca Bianco, Cristiana Ferrero, Stefano Corbetta, Sabrina Vaira, Valentina Front Endocrinol (Lausanne) Endocrinology Long non-coding RNAs (lncRNAs) are an important class of epigenetic regulators involved in both physiological processes and cancer development. Preliminary evidence suggested that lncRNAs could act as accurate prognostic and diagnostic biomarkers. Parathyroid cancer is a rare endocrine neoplasia, whose management represents a clinical challenge due to the lack of accurate molecular biomarkers. Our previous findings showed that human parathyroid tumors are characterized by a different lncRNAs signature, suggesting heterogeneity through the different histotypes. Particularly, we found that the lncRNA BC200/BCYRN1 could represent a candidate biomarker for parathyroid carcinomas (PCas). Here we aimed to extend our preliminary data evaluating whether BC200 could be an accurate non-invasive biomarker of PCas to support the clinical management of patients affected by parathyroid tumors at diagnosis, prognosis and follow-up. To provide a non-invasive point-of-care for parathyroid carcinoma diagnosis and follow-up, we analyzed BC200 expression in patients’ serum through digital PCR. Our results show that BC200 counts are higher in serum from patients harboring PCa (n=4) compared to patients with parathyroid adenoma (PAd; n=27). Further, in PAd patients circulating BC200 levels are positively correlated with serum total calcium. Then, we found that BC200 is overexpressed in metastatic PCas (n=4) compared to non-metastatic ones (n=9). Finally, the lncRNA expression in PCa patients’ serum drops are reduced after parathyroidectomy, suggesting its possible use in the post-operative setting for patients follow-up. Overall, these findings extend the knowledge on BC200 in parathyroid tumors, supporting its role as a useful biomarker for management of PCa. Frontiers Media S.A. 2022-05-02 /pmc/articles/PMC9108332/ /pubmed/35586620 http://dx.doi.org/10.3389/fendo.2022.869006 Text en Copyright © 2022 Morotti, Cetani, Passoni, Borsari, Pardi, Guarnieri, Verdelli, Tavanti, Valenti, Bianco, Ferrero, Corbetta and Vaira https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Morotti, Annamaria Cetani, Filomena Passoni, Giulia Borsari, Simona Pardi, Elena Guarnieri, Vito Verdelli, Chiara Tavanti, Giulia Stefania Valenti, Luca Bianco, Cristiana Ferrero, Stefano Corbetta, Sabrina Vaira, Valentina The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma |
title | The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma |
title_full | The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma |
title_fullStr | The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma |
title_full_unstemmed | The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma |
title_short | The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma |
title_sort | long non-coding bc200 is a novel circulating biomarker of parathyroid carcinoma |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108332/ https://www.ncbi.nlm.nih.gov/pubmed/35586620 http://dx.doi.org/10.3389/fendo.2022.869006 |
work_keys_str_mv | AT morottiannamaria thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT cetanifilomena thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT passonigiulia thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT borsarisimona thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT pardielena thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT guarnierivito thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT verdellichiara thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT tavantigiuliastefania thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT valentiluca thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT biancocristiana thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT ferrerostefano thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT corbettasabrina thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT vairavalentina thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT morottiannamaria longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT cetanifilomena longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT passonigiulia longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT borsarisimona longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT pardielena longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT guarnierivito longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT verdellichiara longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT tavantigiuliastefania longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT valentiluca longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT biancocristiana longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT ferrerostefano longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT corbettasabrina longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma AT vairavalentina longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma |